Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | USP2 | O75604 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.40 |
| ▸ | TUBB | P07437 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2929962 | 0.92 | SMN1; SMN2 (0.47) | SMN1; SMN2USP2LMNATSHRALOX15 | |
| SCHEMBL2924630 | 0.89 | SMN1; SMN2 (0.47) | SMN1; SMN2USP2LMNATSHRALOX15 | |
| SCHEMBL2924216 | 0.88 | SMN1; SMN2 (0.53) | SMN1; SMN2USP2LMNATSHRALDH1A1 | |
| SCHEMBL3043512 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2USP2LMNATSHRALDH1A1 | |
| SCHEMBL2930041 | 0.84 | SMN1; SMN2 (0.53) | SMN1; SMN2USP2LMNATSHRALDH1A1 | |
| SCHEMBL2931023 | 0.82 | GAA (0.39) | SMN1; SMN2LMNATSHRKDM4EGAA | |
| SCHEMBL2925831 | 0.82 | SMN1; SMN2 (0.49) | SMN1; SMN2USP2LMNATSHRALOX15 | |
| SCHEMBL2929860 | 0.78 | SMN1; SMN2 (0.47) | SMN1; SMN2USP2LMNATSHRALOX15 | |
| SCHEMBL2876735 | 0.78 | LMNA (0.56) | SMN1; SMN2USP2LMNAALDH1A1HSD17B10 | |
| SCHEMBL2924910 | 0.77 | SMN1; SMN2 (0.47) | SMN1; SMN2USP2LMNATSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534695-B1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090186871-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2009-07-23 | — | — | US | disclosed |
| US-7560546-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2009-07-14 | — | — | US | disclosed |
| EP-1534695-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20050261496-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2005-11-24 | — | — | US | disclosed |
| EP-1534695-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004014851-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261496-A1 | Tyrosine kinase inhibitors | ABL1, JAK2, ERBB2 | SMN1; SMN2 4767/4885USP2 2116/4885LMNA 4850/4885 |
| US-20090186871-A1 | Tyrosine kinase inhibitors | ABL1, JAK2, ERBB2 | SMN1; SMN2 4767/4885USP2 2116/4885LMNA 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.